Table 3: Comparison of the clinical characteristics of patients who developed CMV reactivation versus those who did not.

|  |  |  |  |
| --- | --- | --- | --- |
| **Modality** | **Total number** **210** | **CMV reactivation** | **P-value**  |
| **Yes****Number (%)** | **No****Number (%)** |
| Age groups<50 years≥50 years | 130 (61.9%)80 (38.1%) | 25 (19.2%)12 (15.0%) | 105 (81.5%)68 (85.0%) | 0.44 |
| Underlying diseaseLymphomaMultiple myeloma | 115 (55%)95 (45%) | 23(20.0%)14(14.7%) | 92(80.0%)81(85.3%) | 0.32 |
| Stage of the underlying diseaseStage I/IIStage III/IVUnknown | 100(48%)82(39%)28(13%) | 14(14.0%)17(20.7%)6(21.4%) | 86(86.0%)65(79.3%)22(78.6%) | 0.23 |
| Lines of chemotherapy before transplantation≤ 3 lines>3 linesUnknown | 182(86.6%)25(12%)3(1.4%) | 33(18.1%)3(12.0%)1(33.3%) | 149(81.9%)22(88.0%)2(66.7%) | 0.45 |
| Receipt of Bortezomib before transplantation (multiple myeloma only)YesNo | 10 (10.5%)85 (89.5%) | 3 (30%)11 (12.9%) | 7 (70%)74 (87.1%) | 0.09 |
| Disease status before transplantComplete remission Partial response Stable disease Unknown | 34 (16%)147 (70%)4 (2%)25 (12%) | 7 (20.6%)26 (17.7%)04 (16 %) | 27 (79.4%)121 (82.3%)4 (100%)21 (84%) | 0.59 |
| CMV status before transplantIgG positive IgM positive  | 205 (97.6%)10 (5%) | 37(18.0%)3(30.0%) | 168(82.0%)7(70.0%) | 0.300.29 |
| CMV prophylaxis Acyclovir Valacyclovir Unknown | 198 (94.3)11 (5.2%)1 (0.5%) | 27(13.6%)9(81.8%)1(100%) | 171(86.4%)2(18.2%)0 | < 0.0001 |

CMV: Cytomegalovirus.